A Call for Better Screening for Hereditary Renal Cell Carcinoma

It may be time to adopt a broader approach to tumor and matched normal sequencing in patients with advanced renal cell carcinoma (RCC), according to a large new study.07/13/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

GM2-synthase produces sialic acid–containing glycosphingolipids called gangliosides, and its mRNA overexpression and the gangliosides it generates are linked to tumor progression, migration, and suppression of tumor-specific host immune responses. However, the mechanism underlying GM2-synthase de-repression in renal cell carcinoma (RCC) is poorly understood. Here, we demonstrate that higher GM2-synthase mRNA expression levels in various cancer cells and in human RCC tumors correlate with higher histone acetylation levels (H3K9, H3K14, or both) at region +38/+187 relative to the transcription start site (TSS) of the G...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Glycobiology and Extracellular Matrices Source Type: research
(Spectrum Health) A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors. These factors include multiple measures of obesity, diastolic blood pressure and fasting insulin. In contrast, the study found little evidence for an association with RCC risk for systolic blood pressure, circulating lipids, diabetes or fasting glucose.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
AbstractFor the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As mTOR plays an important role in the immune system, e.g., by controlling the expression of the transcription factor FoxP3 thereby regulating regulatory T cells (Tregs), it plays a key role in the balance between tolerance and inflammation. Previous reports showed stimulatory effects of mTOR inhibition on the expansion of Tregs, an effect that can be considered detrimental in terms of cancer control. Since metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs, a phase 1 clinic...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Splenic metastasis is uncommon and is usually associated with widespread disease.1,2 Isolated splenic metastases from renal cancer are also rarer and are often an incidental finding. This eventuality may turn into a dangerous scenario due to a spontaneous splenic rupture leading to sudden death.2,3 At the best of our knowledge only few cases of metastasis from renal cell carcinoma (RCC) have been documented in the literature.4-11 We hereby present a literature review of these cases and report a case of isolated splenic metastasis in a young man on active follow-up for a clear cell ccRCC.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.01/15/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
ConclusionsThe role of the microbiome in genitourinary cancer is an emerging field that merits further studies. Translating microbiome research into clinical action will require incorporation of microbiome surveillance into ongoing and future clinical trials as well as expansion of studies to include metagenomic sequencing and metabolomics.Patient summaryThis review covers recent evidence that microbial populations that reside in the genitourinary tract—and were previously not known to exist—may influence the development of genitourinary malignancies including bladder, kidney, and prostate cancers. Furthermore,...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Cancer is a life-threatening disease that causes every fourth death. It is often hard to determine the time point of progression. Therefore, biomarkers for cancer entities that indicate disease progression or ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).01/11/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Conclusion Combined HCQ 600mg twice daily with 10 mg daily everolimus was tolerable. The primary endpoint of>40% 6 month PFS rate was met. HCQ is a tolerable autophagy inhibitor in future RCC or other trials. PMID: 30635337 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology